ArticleJournal of skin cancer2013
Merkel cell carcinoma: chemotherapy and emerging new therapeutic options.
Article in Journal of skin cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Guideline
- Merkel cell carcinoma, version 1.2014.Journal of the National Comprehensive Cancer Network : JNCCN · 2014Guideline
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.The Lancet. Oncology · 2016Trial
- Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.International journal of molecular sciences · 2024Review
- Chemoreactive 2,5-Diketopiperazines from aJournal of natural products · 2024Article
- The effect of selinexor on prostaglandin synthesis in virus-positive Merkel cell carcinoma cell lines.Archives of dermatological research · 2024Article
- High-volume facilities are significantly more likely to use guideline-adherent systemic immunotherapy for metastatic Merkel cell carcinoma: implications for cancer care regionalization.Archives of dermatological research · 2024Article
- Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: A case report.Oncology letters · 2022Article
- Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?International journal of molecular sciences · 2021Review
- Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.International journal of molecular sciences · 2021Review
- Gene expression profile identifies distinct molecular subtypes and potential therapeutic genes in Merkel cell carcinoma.Translational oncology · 2020Article
- A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients.Frontiers in oncology · 2020Article
- Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies.Dermatology and therapy · 2019Review
- Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US.ClinicoEconomics and outcomes research : CEOR · 2019Article
- Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.Targeted oncology · 2018Review
- Avelumab: A Review in Metastatic Merkel Cell Carcinoma.Targeted oncology · 2018Review
- PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.Expert review of clinical pharmacology · 2018Review
- Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.Reviews in endocrine & metabolic disorders · 2017Review
- Merkel Cell Carcinoma Therapeutic Update.Current treatment options in oncology · 2016Review
- Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma.Current oncology (Toronto, Ont.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare neuroendocrine skin tumor that typically occurs in elderly, immunosuppressed patients. Infection with Merkel cell virus (MCV) and immunosuppression play an important role in the development of MCC. Different staging systems make it difficult to compare the existing clinical data. Furthermore, there predominantly exist single case reports and case series, but no randomized controlled trials. However, it is necessary to develop further therapy options because MCC tends to grow rapidly and metastasizes early. In the metastatic disease, therapeutic attempts were made with various chemotherapeutic combination regimens. Because of the high toxicity of these combinations, especially those established in SCLC, and regarding the unsatisfying results, the challenge is to balance the pros and cons of chemotherapy individually and carefully. Up to now, emerging new therapy options as molecular-targeted agents, for example, pazopanib, imatinib, or somatostatin analogues as well as immunologicals, for example, imiquimod and interferons, also showed less success concerning the disease-free response rates. According to the literature, neither chemotherapy nor molecular-targeted agents or immunotherapeutic strategies have shown promising effects in the therapy of the metastatic disease of MCC so far. There is a great demand for randomized controlled studies and a need for an MCC registry and multicenter clinical trials due to the tumors curiosity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.